What is lung ablation?
A thin probe is advanced through the chest wall under live CT guidance directly into a lung tumor. Energy — heat from microwave or radiofrequency, or extreme cold from cryoablation — destroys the tumor. The probe is removed at the end. There’s no incision other than the small needle puncture, no chest cracking, no lobe removed.1
Where ablation fits
Surgery and radiation are powerful tools, but not every patient is a candidate for either. Ablation meets patients where they are: when surgery is too risky, when SBRT has already been given, when pulmonary reserve is borderline, or when a limited number of metastases need local control without a major operation or another full course of radiation.
An alternative to surgery
Surgical lobectomy — removing the entire lobe containing the tumor — remains the gold standard for early-stage non-small cell lung cancer (NSCLC) in patients who can tolerate it. Sublobar resection (wedge resection or anatomic segmentectomy) is increasingly used for very small peripheral tumors. But many patients can’t safely have any of these:
- Low pulmonary function — COPD, emphysema, pulmonary fibrosis, or prior resections leave too little reserve to safely remove more lung
- Cardiac disease — coronary disease, heart failure, or rhythm problems that increase thoracic surgery risk
- Age and frailty — biologic age, deconditioning, or comorbidities that raise perioperative risk
- Prior thoracic surgery — previous lobectomy, thoracotomy, or pleurodesis that makes repeat resection unsafe
- Patient preference — informed patients who decline major surgery for a less invasive option
For these patients, ablation provides local treatment without removing healthy lung, without thoracotomy, and without prolonged recovery. Prospective trial data (RAPTURE, ACOSOG Z4033) support its use in medically inoperable stage IA NSCLC.1,3
An alternative to radiation (SBRT)
Stereotactic body radiation therapy (SBRT) and ablation are the two primary local therapies for medically inoperable patients. Both work. Ablation is often the better choice when:
- The tumor recurred after prior SBRT. Repeat radiation is constrained by cumulative dose to lung, esophagus, and spinal cord; ablation can usually still be performed safely.2
- The tumor is near the chest wall, where SBRT can cause significant rib pain or fracture
- Multiple lesions need treatment in oligometastatic disease — ablation can address several in one session without committing the surrounding lung to radiation
- The patient prefers a one-session treatment rather than the multi-session SBRT schedule
- Treatment may need to be repeated — ablation is straightforwardly repeatable; re-irradiation often is not
The reverse is also true: SBRT is sometimes better — particularly for tumors near the central airways or great vessels, where percutaneous ablation carries higher risk. The multidisciplinary thoracic oncology team makes the call.
Microwave vs. radiofrequency vs. cryoablation
Three forms of energy are used; the right one depends on tumor size, location, and proximity to airways and large vessels.
- Microwave ablation (MWA) rapidly heats tissue with electromagnetic energy, producing large predictable ablation zones — the most common modality for primary lung tumors today.2
- Radiofrequency ablation (RFA) uses alternating electrical current to generate heat. Longest track record in lung tumors but creates smaller zones than microwave.
- Cryoablation freezes and thaws the tumor in controlled cycles, producing a visible ice ball on CT — useful for tumors near sensitive structures. Studied prospectively for pulmonary metastases in the ECLIPSE trial.4
How the procedure works
Performed in a hospital interventional suite under general anesthesia or deep sedation. Under live CT guidance, the ablation probe is advanced through the chest wall directly into the tumor. Energy is delivered, and immediate post-procedure CT confirms complete coverage and screens for complications such as pneumothorax — air around the lung, the most common complication, usually managed with a small chest tube. Total procedure time is typically 60 to 120 minutes; most patients are observed overnight and discharged the following day.
Who is a good candidate?
Candidacy is determined by a multidisciplinary thoracic oncology team. Patients commonly considered for lung ablation include those with early-stage NSCLC who aren’t surgical candidates, recurrent NSCLC after prior SBRT or surgery, oligometastatic disease to the lung from primaries such as colorectal, sarcoma, renal cell, breast, melanoma, hepatocellular, head and neck, or gynecologic cancers, limited remaining pulmonary reserve after prior treatment, and selected palliative situations — local control of a symptomatic tumor causing hemoptysis or pain.
References
- Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: a prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9(7):621–628.
- Healey TT, March BT, Baird G, Dupuy DE. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J Vasc Interv Radiol. 2017;28(2):206–211.
- Dupuy DE, Fernando HC, Hillman S, et al. Radiofrequency ablation of stage IA non-small cell lung cancer in medically inoperable patients: results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial. Cancer. 2015;121(19):3491–3498.
- de Baere T, Tselikas L, Woodrum D, et al. Evaluating cryoablation of metastatic lung tumors in patients — Safety and efficacy: the ECLIPSE Trial. J Thorac Oncol. 2015;10(10):1468–1474.
Frequently asked questions
Is lung ablation an alternative to surgery?
Yes, for selected patients. Surgical lobectomy remains the gold standard for early-stage NSCLC in patients who can tolerate it, but many patients can’t safely have surgery — because of low pulmonary reserve, COPD or pulmonary fibrosis, cardiac disease, prior thoracic surgery, age, or personal preference. For these patients, image-guided lung ablation provides local treatment of the tumor without removing healthy lung, without thoracotomy, and without prolonged recovery. Prospective trial data (RAPTURE, ACOSOG Z4033) support its use in medically inoperable stage IA NSCLC.
Is lung ablation an alternative to SBRT (radiation)?
Yes. Stereotactic body radiation therapy (SBRT) and ablation are the two primary local therapies for medically inoperable patients. Ablation is often preferred when the tumor has recurred after prior SBRT (where re-irradiation is constrained by cumulative dose), when the tumor is near the chest wall (where SBRT can cause significant rib pain or fracture), when multiple lesions need treatment in a single session, when the patient prefers a one-session treatment, or when the procedure may need to be repeated. SBRT is sometimes the better choice — particularly for tumors near the central airways or great vessels — and the multidisciplinary team makes the call.
What is lung tumor ablation?
Lung tumor ablation is an image-guided procedure in which a thin probe is advanced through the chest wall directly into a lung tumor under live CT guidance. Energy — heat (microwave or radiofrequency) or extreme cold (cryoablation) — destroys the tumor while sparing surrounding lung. There’s no incision other than the small needle puncture, and most patients are discharged the next day.
What’s the difference between microwave, RFA, and cryoablation?
Microwave ablation (MWA) uses electromagnetic energy to rapidly heat tissue and produces large, predictable ablation zones. Radiofrequency ablation (RFA) uses alternating electrical current and has the longest track record in lung tumors but creates smaller zones. Cryoablation freezes and thaws the tumor in controlled cycles and produces a visible ice ball that can be monitored on CT — useful for tumors near sensitive structures. The choice depends on tumor size, location, and proximity to airways and vessels.
Who is a good candidate?
Lung ablation is most often considered for patients with early-stage NSCLC who can’t safely have surgery, patients with a limited number of pulmonary metastases (oligometastatic disease) where local control is appropriate, and patients with recurrent tumors after prior surgery or radiation. Candidacy is determined by a multidisciplinary thoracic oncology team.
What are the main risks?
The most common complication is pneumothorax (air leak around the lung), which is usually managed with a small chest tube and resolves over a few days. Less common risks include hemoptysis, post-ablation syndrome (low-grade fever and fatigue for a few days), pleural effusion, and rare injury to nearby structures. Serious complications are uncommon in experienced hands.
Will I still need chemotherapy or immunotherapy?
That’s decided by your medical oncologist. Ablation provides local control of the targeted tumor; whether you also receive systemic therapy (chemotherapy, immunotherapy, or targeted therapy) depends on your tumor type, molecular profile, and stage.
